TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Language Assessment Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRI Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GENDOLCAT scale punctuations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in fMRI results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in chronic lower limb ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AUCtau of SOF, GS-331007, VEL, and VOX
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of flare effects
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in size and number of tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reduction in FiO2 > 75%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: HbA1c Progression to diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of grade 3 CNS toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of pregnancies and deliveries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: New or progressive acute kidney injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Illicit opioid abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and percentage of responder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of headache
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of dizziness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in symptoms of anxiety
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Progression free survival
Endpoint domain: Mortality/survival
Primary endpoint: Differences in nycthemeral IOP patterns
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Sensitivity against PAF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Platelet Sensitivity against Thrombin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: In-hospital VTE
Endpoint domain: Adverse events/effects
Primary endpoint: Size and shape of the ablation zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spatial coordinates of the ablation zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Sarcopenia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of Abdominal Hernias
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain on Day 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain on Day 25
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Increase in CD4 lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in trough Forced Expiratory Volume in 1 second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: DNA Stress Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients Alive at 1 Year
Endpoint domain: Mortality/survival
Primary endpoint: Patient-Reported Outcomes Measurement System Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percentage of days with pH levels within range 7 and 8
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time within the margins established as safe in the pH control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measurement of the volume of crystalluria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate for platelet count less than 60 X 10^4/ul
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Repigmentation percentage of the reference lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change from Baseline on The Collusion Framing Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline on The Collusion Labeling Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline on The Collusion Extraneous Information Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from Baseline on The Collusion Negative Characteristics Subscale
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Incidence and Severity of Treatment-Related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in Total Daily Bolus Amount of Exogenous Insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: c-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change from baseline in Asthma Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Detection of clopidogrel resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Serious Adverse Drug Reactions (ADRs)
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma hydromorphone concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability for a virtual reality intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Social self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social interaction and social phobia
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Social paranoia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of saccades and fixations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in right ventricular myocardio strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in mean dental plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in mean gingivitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Colorized waveform
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caregivers' Self-efficacy
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Caregivers' Preparedness
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Caregivers' Competence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Dementia Patients' Behavioral Problems
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oswestry Low-back Pain Disability Questionnaire Score Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: level of root coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: incidence of CMV infection or disease
Endpoint domain: Adverse events/effects
Primary endpoint: Change in cumulative incidence of biologically confirmed STIs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the number of unprotected sex acts
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Change in the Mini - Assisting Hand Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Bayley Infant Scales of Development
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to monotherapy failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Use of specific medicine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hemodynamic outcome of aortic valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fugl-Meyer Assessment of Physical Performance (FM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: upper extremity performance evaluation test for the elderly (TEMPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major adverse cardiovascular events (MACCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Erectile Dysfunction as measured by IIEF-5
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Erection hardness as measured by EHS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-6 gene (174G/C) polymorphism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Complete Response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change in 89Zr-bevacizumab uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of myocardial infarction and stroke events
Endpoint domain: Mortality/survival
Primary endpoint: Plasma CRP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of Oxygen Alarms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants making a second attempt
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in serum antibodies against vaccine-related influenza virus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in the Sidorkiewicz instrument score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Nighttime sleep measured by Polysomnography (PSG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karolinska Sleepiness Scale (KSS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in symptom prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in PbtO2 gross values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of the BD Onclarity™ HPV Assay for the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)2 or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Sensitivity of the BD Onclarity™ HPV Assay for the Detection of Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)3 or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of the BD Onclarity™ HPV Assay for Detecting Cervical Disease as Defined by Cervical Intraepithelial Neoplasia (CIN)2 or Greater
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes on global perceived effect scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in ASIA impairment scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hospital Readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Spanish version of the SF-36 questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change from baseline in the number of HPV positive anal swabs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change from baseline in the number of dysplastic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean time to therapeutic levels of plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comprehension of the report card
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: sensitivity of IV contrast for CT scan diagnosis of appendicitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skeletal muscle index (SMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative skeletal muscle index (RASM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fat body mass (FBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Failure of ambulatory surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of Mycophenolic Acid in maintaining treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postpartum family planning utilization rate
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in QTc Based on QTcI at Time of Patch Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Production and clearance rates of intestinal TRL-apoB48
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Tolerance of peanuts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Adverse Events Due to MSOT Imaging
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluate Skin Temperature Pre and Post Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Adolescent Girls With PCOS Successfully Recruited
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of complete wound healed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Treatment emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Biomarkers in Idiopathic Pulmonary Fibrosis (IPF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total Volume (ml/kg) of Allogeneic Blood Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Patients That Remained Transfusion Free
Endpoint domain: Adverse events/effects
Primary endpoint: Gene expression of calcineurin in T-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Calcineurin activity measured in whole blood and in isolated T-lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interferon-gamma production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from Baseline in AUASS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in I-QOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Electroencephalogram pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Urges to Self-injure
Endpoint domain: Adverse events/effects
Primary endpoint: Diagnostic accuracy of elastography for thyroid cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Score of Boston Bowel Preparation Scale (BBPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Recidive free survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Superoxide dismutase (SOD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in carotid intima-media thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety assessed by vital signs: blood pressure (systolic blood pressure and diastolic blood pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Frequency of Psychological distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline Tumor necrosis factor alpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change from baseline Oxidative stress marker malondialdehyde
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of nonadherence events on myelosuppression severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact of nonadherence events on patient morbidity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Effect of an automated notification program on adherence rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Improvement of Disease activity index score (DAI score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Metabolic Response (CMR) rate prior to HDCT/ASCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Complete Metabolic Response (CMR) rate at any time prior to radiation therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Minimum active dose of CSJ137 determined by assessment of levels of hemoglobin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RGD-tracer uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: CT perfusion flow parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Percent of women rescreened for chlamydia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Interstitial glucose values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Glucose uptake into peripheral skeletal muscle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in pure-tone hearing thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral quadriceps muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Muscle quality evaluation through ultrasound images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: freedom from biochemical failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in monthly income of healthcare Providers
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: PTSD CheckList-5 (PCL-5)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of New PrEP Prescriptions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Adherence to moxa regimen
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Change in blood glucose response from baseline for 3 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma insulin response from baseline for 3 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under the blood glucose concentration versus time curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Successful Test Results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vaginal Stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: User Preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: incidence of chronic neurotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of men tested for HIV
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Presence of chronic venous disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Slit Lamp Findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Additional drug use
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With Immunoglobulin G (IgG) Level Less Than 3 Gram Per Liter (g/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent Change From Baseline in Vital Signs and Routine Safety Lab Parameters at Week 32
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of treatment against Cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Amplitude of the motor evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Surface of the motor evoked potentials
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: TMS threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Blood pressure assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes